Market Overview

Morgan Stanley Speculates On Potential Abbott Laboratories Transaction

Related ABT
Markets Sell-Off After Malaysian Airline Crash In Ukraine
UPDATE: Morgan Stanley Reiterates On Abbott Laboratories As Growth and Margins Are Set To Continue
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “Abbott is a unique healthcare asset, with high exposure to emerging markets and consumer- directed businesses, driving the potential for sustainable double digit earnings growth. Leverage opportunities are highly visible in both Nutritionals and Diagnostics, where peer margins demonstrate the potential for improvement. Expectations are low for the established pharma business, which has come under pressure in the developed markets and presents the potential for reacceleration as emerging market mix grows over time and austerity measures are lapped.”

Abbott Laboratories closed on Friday at $38.56.

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters